NEW YORK (GenomeWeb) – Hologic said today that its subsidiary Tepnel Pharma Services has been designated an authorized Affymetrix service provider. Tepnel is now offering Affy's OncoScan FFPE Assay to its customers as part of its molecular genetics services portfolio.
David Scott, Tepnel's senior director of commercial services, said in a statement that the authorization and launch demonstrate the company's commitment to providing its customers with "access to a wide range of technologically advanced products and services that help them realize the requirements of their research, clinical, and companion diagnostics projects."
Affy's OncoScan FFPE Assay relies on the Santa Clara, Calif.-based company's molecular inversion probe technology, and is designed to analyze small amounts of highly degraded DNA from formalin-fixed, paraffin-embedded samples, enabling solid tumor cancer analysis.
Padma Sundar, marketing director for Affy's clinical applications business unit at Affy, called the assay a "quick and affordable way to analyze degraded FFPE samples to correlate copy number aberrations found across the genome with outcomes data."
Tepnel is also a certified service provider of Illumina microarrays. The UK-based contract research organization also offers Luminex multiplexing and Thermo Fisher Scientific Ion Torrent next-generation sequencing services.